304
Participants
Start Date
June 20, 2012
Primary Completion Date
July 24, 2013
Study Completion Date
June 12, 2014
CD5789 25 µg/g cream
CD5789 25 µg/g cream applied once daily
CD5789 50 µg/g cream
CD5789 50 µg/g cream applied once daily
CD5789 100 µg/g cream
CD5789 100 µg/g cream applied once daily
Tazarotene 0.1% gel
Tazarotene 0.1% gel applied once daily
Vehicle cream
Vehicle cream applied once daily
The Education & Research Foundation, Inc., Lynchburg
Zoe Drealos, MD, High Point
PMG Research of Wilmington, Wilmington
Palmetto Clinical Trial Services, LLC, Greenville
Meda Phase, Inc, Newnan
FMX Research Miramar, Miramar
FXM Research Corp Miami, Miami
Total Skin and Beauty Dermatology Center, PC, Birmingham
Dermatology Specialists PC, Louisville
Deaconess Clinic, Inc., Evansville
Hamzavi Dermatology, Fort Gratiot
Somerset Skin Centre, Troy
Skin Specialists, PC, Omaha
Central Sooner Research, Norman
Arlington Center for Dermatology, Arlington
Suzanne Bruce and Associates P.A. The Center for Skin Research, Houston
Center for Clinical Studies, Webster
Stephen Miller MD, San Antonio
Dermatology Research Center, Salt Lake City
Academic Dermatology Associates, Albuquerque
Odyssey Medispa, Marina del Rey
Parexel Early Phase, Glendale
Rady Children's Hospital, San Diego
Oregon Dermatology and Research Center, Portland
Lead Sponsor
Galderma R&D
INDUSTRY